10-K: Edwards Lifesciences Reports Strong 2025 Sales Growth

Edwards Lifesciences reported a significant increase in net sales for 2025, driven by strong performance in its TAVR and TMTT product groups, despite a decrease in net income due to higher operational and litigation expenses.

Summary

• Net sales for 2025 reached $6.1 billion, an increase of $628.1 million (11.5%) over 2024, primarily driven by growth in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) products.
• TAVR product sales increased by 9.3% to $4,487.7 million, while TMTT product sales saw a substantial 56.4% increase to $550.6 million.
• Surgical Structural Heart product sales grew by 4.9% to $1,029.3 million.
• Gross profit increased in 2025, but gross profit as a percentage of sales decreased due to higher operational expenses.
• Net income and diluted earnings per share decreased in 2025, primarily due to increases in personnel-related costs, one-time charges related to investment impairments, and increased litigation expenses.
• Research and development (R&D) spending increased approximately 2% year-over-year, representing 18% of 2025 sales.
• The company completed the sale of a non-core product group on December 18, 2025, for $81.8 million upfront, with potential earnouts of up to $40.0 million.
• A $146.9 million loss on impairment was recorded in 2025 related to an investment in a promissory note (JenaValve) and the decision not to exercise an option to acquire another medical device company.
• Intangible assets impairment charges of $40.0 million were recognized in 2025 related to certain developed technology assets.
• The Israel Tax Authority (ITA) withdrew its $110.0 million assessment related to a claimed 2017 intellectual property transfer, agreeing that no such transfer occurred.
• The company paid the final installment of $78.5 million related to the 2017 Tax Cuts and Jobs Act deemed repatriation tax in the second quarter of 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While top-line growth in core structural heart segments is robust and strategic divestitures are complete, substantial litigation expenses and impairment losses have significantly impacted profitability, raising concerns about near-term earnings stability.

Positives

• Net sales increased by 11.5% to $6.1 billion in 2025, demonstrating strong top-line growth.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales surged by 56.4% to $550.6 million, indicating successful commercialization and adoption of new therapies like PASCAL, EVOQUE, and SAPIEN M3 systems.
• Transcatheter Aortic Valve Replacement (TAVR) sales grew by 9.3% to $4,487.7 million, driven by the SAPIEN platform and new approvals.
• Received United States FDA approval for the SAPIEN 3 platform for severe asymptomatic aortic stenosis patients.
• Received FDA and CE Mark approval for the SAPIEN M3 mitral valve replacement system, launching the first transcatheter therapy utilizing a transseptal approach for symptomatic mitral regurgitation.
• Received a CE Mark for and launched in Europe the KONECT RESILIA aortic valved conduit, a ready-to-implant solution for complex combined procedures.
• New eight-year data demonstrated over 99% freedom from structural valve deterioration for RESILIA tissue technology, setting a new standard for tissue valve durability.
• ENCIRCLE pivotal trial results showed successful patient outcomes for mitral and tricuspid therapies.
• Seven-year data from the PARTNER 3 trial reaffirmed early and sustained patient benefits of Edwards TAVR.
• Net cash provided by operating activities significantly increased to $1,595.2 million in 2025 from $542.3 million in 2024.
• The Israel Tax Authority (ITA) agreed that intellectual property was not transferred in 2017 and withdrew its $110.0 million assessment, resolving a significant tax dispute.
• Settled litigation with Fortis Advisors related to the Harpoon Medical acquisition, with claims dismissed with prejudice.

Negatives

• Net income from continuing operations decreased to $1,056.0 million in 2025 from $1,396.0 million in 2024.
• Diluted earnings per share from continuing operations decreased to $1.81 in 2025 from $2.34 in 2024.
• Gross profit as a percentage of sales decreased in 2025, primarily due to higher operational expenses.
• Intellectual property agreement and certain litigation expenses significantly increased to $325.4 million in 2025 from $40.4 million in 2024.
• A $146.9 million loss on impairment was recorded in 2025 related to an investment in a promissory note and an option to acquire a variable interest entity (VIE).
• Intangible assets impairment charges of $40.0 million were recognized in 2025.
• The effective income tax rate increased to 17.0% in 2025 from 9.8% in 2024, partly due to the impact of Pillar Two provisions and certain non-deductible litigation expenses.
• The proposed acquisition of JenaValve Technology, Inc. was blocked by the U.S. Federal Trade Commission (FTC) and subsequently terminated due to an injunction.
• The company withdrew its Advance Pricing Agreement (APA) renewal application between Japan and the United States for tax years 2025 through 2029 due to ongoing supply chain changes.
• An ongoing dispute with the IRS regarding transfer pricing for 2015-2017 tax years involves a proposed additional tax of $269.3 million, which the company plans to vigorously contest.

Risks

• Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could render existing products obsolete or less competitive.
• Unsuccessful clinical trials or procedures could adversely affect the ability to obtain necessary regulatory approvals and market acceptance.
• Manufacturing, logistics, safety, or quality problems, including raw material cost volatility and supply interruptions, could materially adversely affect the business.
• Operating in highly competitive markets with established and newer technologies, including drug therapies, could harm the business.
• Dependence on key physicians, research institutions, and hospital systems, and potential limitations on their engagement or facility availability, could impact product development and sales.
• Public health crises, including pandemics and epidemics, could disrupt business operations, hospital systems, and supply chains.
• Reliance on third parties for raw materials, components, and sterilization, including single sources, could lead to delays and increased costs.
• The use of, or failure to effectively and timely utilize, emerging technologies, including artificial intelligence (AI), could adversely impact business and financial results.
• Failure to protect information technology infrastructure and products against cybersecurity attacks, network security breaches, service interruptions, or data corruption could materially disrupt operations.
• Inability to recruit and retain qualified talent or execute management succession plans could adversely affect business and operations.
• Failure to successfully integrate acquired businesses, technologies, or strategic alliances, or challenges related to divestitures, could adversely affect business and results of operations.
• Risks associated with the sale of the Critical Care product group, such as increased operational complexity and diversion of management's attention.
• Adverse impacts from global economic, political, and social conditions, including inflation, interest rates, tax law changes, and tariffs.
• International operations subject the company to risks such as trade protection measures, global regulations, military conflict, and currency exchange rate fluctuations.
• Government or other third-party payors declining to reimburse customers for products or imposing cost containment measures could harm profitability.
• Continued consolidation in the healthcare industry could lead to increased purchasing power of customers and downward pressure on product pricing.
• Inability to protect intellectual property or defend against intellectual property claims from third parties could have a material adverse effect.
• Healthcare legislation and other rigorous governmental regulations (e.g., FDA, EU MDR, MRA with Switzerland) may adversely impact access to and demand for products, and non-compliance could lead to substantial sanctions.
• Risks related to domestic and foreign income and non-income taxes, including changes in tax laws (e.g., Pillar Two rules) and ongoing tax audits (e.g., IRS transfer pricing dispute).
• Failure to comply with data privacy and security laws (e.g., HIPAA, GDPR, CCPA/CRPA) could result in significant legal liability and reputational harm.
• Losses from product liability or other claims, inherent in the design, manufacture, and marketing of medical technologies, could adversely affect operating results.
• Litigation, investigations, and other legal proceedings could materially adversely affect financial condition and divert management's attention.
• Use of products in unapproved circumstances could expose the company to liabilities.
• Environmental, health, and safety regulations could result in substantial costs.
• Climate change, or legal, regulatory, or market measures to address climate change, may materially adversely affect financial condition and business operations.
• Risks arising from concerns and/or regulatory actions relating to animal-borne illnesses (e.g., mad cow disease) due to the use of bovine tissue in certain products.

Future Outlook

The company anticipates future growth opportunities by offering solutions for treating patients with both valvular and non-valvular structural heart disease, such as heart failure. Capital expenditures are projected to be approximately $280.0 million in 2026 as investments in operations continue. The company will continue to evaluate the potential effects of the Pillar Two rules on its effective tax rate and expects the Israel Tax Authority's 2018-2022 assessment to be withdrawn. The company plans to vigorously contest the additional tax claimed by the IRS through the judicial process, with a final resolution not expected within the next 12 months. The One Big Beautiful Bill Act (OBBBA) is not expected to have a material impact on future periods.

Management Comments

• "Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives."
• "Our vision is to transform patient care where patients are diagnosed earlier, treated in a routine fashion, live longer, and enjoy a better quality of life."
• "Edwards remains committed to its strategy of transformative product innovation, high-quality, expansive clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes."
• "We are dedicated to generating robust clinical, economic, and quality-of-life evidence increasingly expected by patients, clinicians, and payors in the current healthcare environment, with the goal of encouraging the adoption of innovative new medical therapies that demonstrate superior outcomes."
• "We believe the demand for surgical structural heart therapies is growing worldwide, and that our innovation strategy will continue to strengthen our leadership and positive impact on patients."
• "We are committed to providing high-quality products to patients and have implemented modern quality systems and concepts throughout the organization."
• "We are committed to providing a safe and healthy workplace and complying with all relevant regulations and medical technology industry standards."
• "We are engaged in ongoing research and development to deliver clinically advanced new products, to enhance the effectiveness, ease of use, safety, and reliability of our current leading products, and to expand the applications of our products as appropriate."
• "We believe that adequate amounts of tax and related penalty and interest have been provided for any adjustments that may result from our uncertain tax positions."
• "Management does not believe that any loss relating to the Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows."

Industry Context

StockSavvy.ai notes that Edwards Lifesciences operates in the highly competitive and evolving medical technology industry, specifically the cardiovascular segment, which is the number-one cause of death globally. The company's focus on transformative product innovation and robust clinical evidence aligns with the industry's increasing emphasis on value-based healthcare and improved clinical outcomes. The divestiture of its Critical Care product group and non-core product group indicates a strategic sharpening of focus on implantable structural heart innovations, a trend seen across specialized medical device companies. Competition from major players like Medtronic and Abbott, along with numerous smaller companies, necessitates continuous R&D investment and differentiation. The increasing regulatory scrutiny and cost-containment efforts by payors globally are significant industry headwinds, requiring companies to demonstrate clear value propositions.

Comparison to Industry Standards

• The SAPIEN platform is highlighted as the most studied transcatheter heart valve globally, with over 15 years of distinguished clinical trials involving over 10,000 patients, 10 New England Journal of Medicine publications, and 1.2 million patients treated worldwide, setting a high benchmark for clinical evidence generation compared to competitors like Medtronic and Abbott.
• RESILIA tissue technology demonstrates over 99% freedom from structural valve deterioration through eight years, establishing a new standard for tissue valve durability in surgical structural heart therapies, differentiating it from other bioprosthetic valves in the market.
• The EVOQUE system is recognized as the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval, positioning the company as a pioneer in this specific therapeutic area against emerging competitors.

Management Changes

Corporate Governance

Legal Proceedings

• Aortic Innovations LLC filed a lawsuit on September 28, 2021, alleging patent infringement by the SAPIEN 3 Ultra product; the Federal Circuit affirmed the district court's claim construction in favor of the company on October 27, 2025, with a trial for remaining claims scheduled for March 23, 2026.
• Cardiovalve, Ltd. and MTH IP, L.P. filed a lawsuit on January 14, 2026, alleging patent infringement by the company's PASCAL products, seeking damages and a permanent injunction.
• The European Commission closed its preliminary investigation into the company's business practices (including its unilateral pro-innovation policy and patent enforcement) on February 15, 2026, without a finding of wrongdoing.
• Valtech Shareholder Representative LLC filed a complaint on February 16, 2026, alleging breach of contract and seeking accelerated milestone payments related to the acquisition of Valtech Cardio Ltd.
• Fortis Advisors, LLC's lawsuit, filed March 22, 2024, alleging breach of the Harpoon Medical, Inc. merger agreement, was confidentially settled on December 1, 2025, and dismissed with prejudice on December 16, 2025.
• A securities class action (Patel v. Edwards Lifesciences Corporation, et al.) was filed on October 14, 2024, alleging violations of securities laws; a motion to dismiss was granted in part and denied in part on September 19, 2025.
• Shareholder derivative actions (Ho v. Zovighian, et al. and Sheridan v. Zovighian, et al.) were filed in late 2024 and early 2025, consolidated on April 10, 2025, and stayed until the Securities Class Action is resolved.
• The company is vigorously contesting an IRS Notice of Deficiency (NOD) for $269.3 million related to transfer pricing for the 2015-2017 tax years, with final resolution not expected within 12 months.
• The Israel Tax Authority (ITA) withdrew its $110.0 million assessment related to a claimed 2017 intellectual property transfer in Q3 2025, and the company expects the related 2018-2022 assessment to also be withdrawn.
• The U.S. District Court granted the FTC's injunction blocking the proposed acquisition of JenaValve Technology, Inc. on January 9, 2026, leading to the termination of the Merger Agreement on January 14, 2026.
• The company has accrued for a payment and agreed to other conditions to resolve a dispute with the FTC regarding its decision not to file a Hart Scott Rodino notice for its acquisition of JC Medical, Inc.

Stakeholder Impact

• Shareholders: Experience decreased net income and diluted EPS due to increased litigation and impairment costs, but benefit from strong sales growth in core product segments and ongoing stock repurchase programs. Face uncertainty from ongoing legal and tax disputes.
• Employees: Benefit from comprehensive human capital management strategies, including talent development, competitive compensation, and well-being programs. Some employees were impacted by a global workforce realignment in 2024.
• Customers (Hospitals, Physicians): Benefit from continued innovation in structural heart therapies (TAVR, TMTT, Surgical), supported by extensive clinical evidence and customer support. Face industry trends of cost-containment and consolidation.
• Patients: Benefit from life-changing innovations designed to treat advanced cardiovascular disease, aiming for earlier diagnosis, improved treatment, longer lives, and better quality of life.
• Suppliers/Vendors: The company relies on a diverse range of raw materials and components, including single-source suppliers, and works to mitigate supply chain risks.
• Creditors: The company maintains a $750.0 million multi-currency unsecured revolving credit facility with no outstanding borrowings as of December 31, 2025, and has $600.0 million in fixed-rate senior notes due 2028.

Next Steps

• Vigorously contest the additional tax claimed by the IRS related to transfer pricing issues for the 2015 through 2017 tax years through the judicial process.
• Defend against the Aortic Innovations LLC lawsuit, with a trial scheduled to begin on March 23, 2026.
• Defend against the newly filed patent infringement lawsuit by Cardiovalve, Ltd. and MTH IP, L.P. regarding PASCAL products.
• Defend against the complaint filed by Valtech Shareholder Representative LLC alleging breach of contract and seeking accelerated milestone payments.
• Continue to defend against the Securities Class Action and the consolidated shareholder derivative actions.
• Monitor and evaluate the potential effects of Pillar Two rules on the effective tax rate as countries continue to enact and refine them.
• Anticipate making capital expenditures of approximately $280.0 million in 2026 to continue investing in operations.
• Bernard J. Zovighian's 10b5-1 trading plan commences on May 12, 2026.
• Donald E. Bobo, Jr.'s 10b5-1 trading plan commences on June 2, 2026.
• Daniel J. Lippis's 10b5-1 trading plan commences on May 18, 2026.
• Integrate the newly acquired medical device company (acquired in February 2026) and work towards achieving milestones for potential contingent consideration payments of up to $132.5 million.

Key Dates

Recommendation

Edwards Lifesciences demonstrates robust top-line growth, particularly in its innovative TAVR and TMTT segments, reinforcing its market leadership in structural heart therapies. However, the significant decline in net income and diluted EPS, driven by substantial litigation expenses, asset impairments, and an increased effective tax rate, presents a concerning picture for near-term profitability. The blocked JenaValve acquisition and ongoing IRS dispute add layers of uncertainty. While the company's strategic focus on innovation and patient outcomes is strong, investors should hold to assess the resolution of these financial and legal headwinds before considering further investment.

Keywords

Edwards Lifesciences, EW, Medical Devices, Structural Heart Disease, TAVR, Transcatheter Aortic Valve Replacement, TMTT, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, SAPIEN, PASCAL, EVOQUE, RESILIA, Heart Valve, Aortic Stenosis, Mitral Regurgitation, Tricuspid Regurgitation, Heart Failure, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Factors, Intellectual Property, Acquisitions, Divestitures, Clinical Trials, FDA, CE Mark, Reimbursement, Cybersecurity, Tax